Instituto do Cancer do Estado de Sao Paulo, 2022-08-09: Terminated Brazilian phase II trial of ivermectin plus losartan as early COVID-19 treatment in patients who had cancer; 77 participants, no results posted.
Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
Instituto do Cancer do Estado de Sao Paulo, 2022-08-09: Terminated Brazilian phase II trial of ivermectin plus losartan as early COVID-19 treatment in patients who had cancer; 77 participants, no results posted. C1 record field. Country Brazil; phase 2; actual enrollment 77; status TERMINATED; start 2020-07-23, primary completion 2022-06-30; no results posted. This trial concerns COVID-19 in cancer patients, NOT antitumour activity; it bears on the claim only as an ivermectin trial that enrolled cancer patients. Comparator: placebo. Included for completeness and because it is the only completed/terminated ivermectin trial in a cancer population on ClinicalTrials.gov. Study type: regulatory record.
